- Home
- AHCO vs XERS Comparison
AHCO vs XERS Comparison
Compare AHCO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHCO | XERS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AHCO | XERS |
|---|---|---|
| Price | $10.84 | $8.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $13.50 | $10.83 |
| AVG Volume (30 Days) | 1.3M | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $3,244,857,000.00 | $49,590,000.00 |
| Revenue This Year | $9.00 | $34.37 |
| Revenue Next Year | $6.93 | $22.86 |
| P/E Ratio | ★ N/A | $841.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $8.51 | $4.87 |
| 52 Week High | $13.43 | $10.08 |
Technical Indicators
Market Signals| Indicator | AHCO | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 56.23 |
| Support Level | $10.80 | $8.00 |
| Resistance Level | $12.87 | $8.42 |
| Average True Range (ATR) | 0.40 | 0.37 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 55.61 | 30.39 |
Price Performance
Historical ComparisonAbout AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.